Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Colin Love"'
Autor:
Howard Goldsweig, Thomas Amatruda, Howard L. Kaufman, Tony Reid, Mike Nemunaitis, Neil Senzer, Gregory Daniels, John A. Glaspy, Tracey Marshall, John Nemunaitis, Rene Gonzalez, Colin Love, Eric D. Whitman, Robert Coffin, Kevin J. Harrington
Publikováno v:
Journal of Clinical Oncology. 27:5763-5771
Purpose Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease. Patients and Methods Trea
Autor:
Ceri J. Davis, Nicholas D. James, Nicola J. Graham, Iain A. McNeish, Colin Love, Natasha Groves, Hardev Pandha, Agnieszka Michael, Jan Steiner, Neil Steven, R. Charles Coombes, Kevin J. Harrington, Peter J. Guest, Christopher M. Nutting, Robert S. Coffin, Julie Simpson, Dennis Wright, Jennifer C.C. Hu, Claire A. Shorrock, Louise C. Medley
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(22)
Purpose: To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco VEXGM-CSF) to determine the safety profile of the virus, look for evidence of
Autor:
B. Hamilton, Robert Coffin, Iain A. McNeish, Christopher M. Nutting, A. Sibtain, Kevin J. Harrington, Colin Love, Mohan Hingorani
Publikováno v:
Journal of Clinical Oncology. 25:14095-14095
14095 Background: OncoVEXGM-CSF is a second generation oncolytic herpes virus expressing GM-CSF which has previously completed a Phase I study with evidence of anti-tumor activity. Combination of OncoVEXGM-CSF with CRT has additionally demonstrated s
Autor:
Colin Love, Agnieszka Michael, J. C. Hu, Hardev Pandha, Robert Coffin, Neil Steven, C. Coombes, C. J. Davis, Nicholas D. James, Jan Steiner
Publikováno v:
Journal of Clinical Oncology. 23:3099-3099
3099 OncoVEXGM-CSF is a second generation oncolytic HSV expressing GM-CSF. Deletion of ICP34.5 provides tumour selectivity. Oncolytic potency is increased using a clinical virus strain, and by expr...